December 09, 2020
PROMISING NEW TREATMENT
CytoAgents, based in Pittsburgh, says it is beginning its Phase 1 clinical trial for a new drug showing promise in the treatment of COVID-19.
Media Coverage
December 09, 2020
CYTOAGENTS WORKING ON DRUG TO TREAT COVID-19
In a press conference Wednesday afternoon, the Department of Community and Economic Development introduced CytoAgents, a Ben Franklin Technology Partners company.
December 09, 2020
NEW COVID-19 TREATMENT SHOWS ENCOURAGING EARLY RESULTS, NORTH SHORE BIOTECH COMPANY SAYS
A North Shore biotech company is reporting encouraging early clinical results for a new COVID-19 treatment that targets the disease’s inflammatory process.
December 09, 2020
HOW CYTOAGENTS’ PLANS FOR GROWTH RUN FAR BEYOND COVID CRISIS
GP1681 “has the potential to be the next best practice in medicine in areas with significant unmet need,” CytoAgents CEO Teresa Whalen said.
October 18, 2020
INTERVIEW WITH TERESA WHALEN, CEO – OUR REGION’S BUSINESS ON WPXI-TV
CytoAgents CEO, Teresa Whalen, RPh spoke with Bill Flanagan at WPXI-TV about our lead drug candidate GP1681 entering clinical trials. She discussed how GP1681 is designed to calm the “cytokine storm,” a condition triggered by COVID-19, influenza, and other respiratory viruses. Often,…